Melanotan-2 mole changes and skin-cancer risk: what's documented

Melanotan-2 is sold as a sunless tan with a libido bonus. What's actually documented is a peptide that broadly switches on melanocyte-stimulating hormone activity across your skin, not a spray tan in a vial. That distinction is why mole and pigment changes show up on the safety side of every serious writeup of this compound, and why a screening conversation belongs before the first injection, not after a new spot appears.

What Melanotan-2 actually does

Melanotan-2 is a melanocortin agonist. It stimulates melanocyte activity broadly rather than at one targeted spot, and it still needs UV exposure to produce a tan, so "no sun tanning peptide" undersells what's happening under the skin. It sits at a weak evidence tier: not FDA-approved, with safety concerns flagged wherever it's covered in serious compound references.

The mole and skin-cancer question

The clinical read on Melanotan-2 is direct: it can accelerate skin-cancer growth, which is why melanoma or skin-cancer history gets screened before anyone considers it, the same way GHK-Cu and BPC-157 get screened for angiogenesis risk in people with an active cancer history. Female-focused protocol notes go further and flag Melanotan-2 for mole and pigment changes specifically, with skin surveillance required and the compound not recommended.

Because the mechanism is a broad hormonal push on melanocyte activity, not a localized effect, a new or darkening mole that shows up during a Melanotan-2 run is a dermatology question, not a "give it a few weeks" cosmetic side effect. That's the actual case for screening before you start: once a mole has changed, distinguishing "this is what the compound does" from "this needs a biopsy" is a specialist call, not a self-diagnosis.

Verify what's actually in the vial

There's a second layer of risk that compounds the first one: gray-market Melanotan-2 isn't always Melanotan-2. The most-cited case in circulation is a man whose skin darkened on what he'd bought as "retatrutide" and turned out to be Melanotan-2 instead. If you're already accepting a pigmentation and skin-cancer risk profile for a specific compound, you need certainty that's the compound you're actually injecting, not a guess based on a label.

That means a COA with purity percentage, mass-spec confirmation, and an endotoxin line, not a vendor's word. No mass spec, no endotoxin data, or suspiciously round purity numbers are the standard red flags. See how to verify a peptide COA and the broader red flags to check before you order for what that verification actually looks like.

If the goal is libido, not tan, there's a different path

If the real want is the libido effect and the tanning is incidental, that's a materially different risk conversation. Bremelanotide (PT-141) works on the brain's arousal centers rather than through broad melanocyte stimulation, and it's the FDA-approved version for women (marketed as Vyleesi). That's a legal medication with a defined evidence base, not a research-chemical order with an unscreened skin-cancer signal attached.

What a screening conversation covers

Before Melanotan-2 gets recommended, the questions worth putting to a clinician are: personal or family melanoma and skin-cancer history, a baseline check of existing moles so anything new during the run is traceable rather than guessed at, and whether the libido or cosmetic goal is better served by an approved alternative. That conversation belongs with a dermatologist or your prescribing clinician, not a forum thread.

Full protocol context lives on the Ouros Lab feed, including how other compounds get screened for the same class of risk.

FAQ

Is Melanotan-2 FDA-approved?

No. It sits at a weak evidence tier with documented safety concerns, unlike bremelanotide (PT-141/Vyleesi), which is FDA-approved for a related but mechanistically different use.

Does Melanotan-2 cause new moles, or just darken existing ones?

What's documented is mole and pigment changes serious enough to require skin surveillance and a melanoma/skin-cancer history screen before anyone considers the compound. Whether a specific change is a new mole, a darkened existing one, or something that needs a biopsy is a dermatologist's call on the actual mole, not a general answer.

Is there a way to get the tan without the mole and skin-cancer risk?

Not through this compound. Melanotan-2's mechanism is a broad, non-targeted push on melanocyte activity, which is the same mechanism behind the mole and skin-cancer flags. If the underlying goal is libido rather than tanning, PT-141/bremelanotide addresses that through a different pathway with an FDA-approved version available.

How do I know if my Melanotan-2 vial is actually Melanotan-2?

Ask for a COA with purity percentage, mass-spec confirmation, and an endotoxin line. Gray-market product is batch-to-batch unverifiable, and the most-cited public case of this exact failure was a buyer who thought he had retatrutide and was actually injecting Melanotan-2.